Parenteral Nutrition Market

Parenteral Nutrition Market Outlook (2022-2032)

The market for parenteral nutrition accrued significant gains, being valued at over US$ 6 Billion as of 2021.

The industry is expected to reach US$ 7 Billion by 2022-end, experiencing year on year increase of 16% compared to 2021. From 2022-2032, the industry is forecast to increase 2x to reach US$ 14 Billion.

Report Attributes	Details
Market Value for 2021	US$ 6 Billion
Anticipated Market Value for 2022	US$ 7 Billion
Forecasted Market Value for 2032	US$ 14 Billion
Global Growth Rate (2022-2032)	7% CAGR
Market Share of North America	42%
Value CAGR of Asia-Pacific	8%
Market Share of Single Dose Amino Acids	31%
Key Companies Profiled	Allergan Plc. Baxter International Vifor Pharma Group Grifols S.A Otsuka Pharmaceutical Co. Ltd. Fresenius Kabi B. Braun Melsungen AG Pfizer Inc. Sichuan Kelun Pharmaceutical Co. Ltd. Actavis Inc.

Parenteral Nutrition Demand Analysis 2015-2021 vs. Future Market Outlook 2022-2032

According to Fact.MR- a market research and competitive intelligence provider- parenteral nutrition products experienced a significant uptick in sales, flourishing at a CAGR of 6.4% from 2015 to 2021.

Rising demand for enhancing nutrition intake amongst immunocompromised patients due to the onset of chronic or infectious ailments has led to this high uptake.

During the COVID-19 pandemic, prospects further elevated, as healthcare providers relied on parenteral administration of vital body fluids and nutrients. Given the highly inflammatory nature of the disease, patients were rendered unable to consume nutrients orally, prompting parental nutrients administration. Moreover, it helped caretakers avoid contracting the infection themselves.

As the world population continue to expand, nutritional requirements are expected to surge manifold, especially across the low and middle-income countries.

Government initiatives to curb the incidence of malnutrition across these regions is opening new growth frontiers for parenteral nutrition products. As per this report, the market is forecast to experience a CAGR of 7% across the 2022-2032 assessment period.

Prominent Drivers Influencing Parenteral Nutrition Industry Expansion

Rising Prevalence of Chronic, Non-Communicable Diseases to Augment Growth

Non-communicable diseases (NCDs) lead to 41 million fatalities each year, equivalent to 71% of deaths globally, according to the World Health Organization. Each year, more than 15 million people die from an NCD between the ages of 30 and 69 years, and 85% of these premature deaths occur across low and middle-income countries.

Most of these fatalities arise out of lack of adequate minerals, vitamins or nutrients. Malnutrition is a serious problem plaguing both the developing as well as developed worlds. Currently, nearly 2 billion adults are overweight or obese, while 462 million are underweight.

Attributed to these disturbing trends, healthcare facilities worldwide are emphasizing on the importance of balancing nutritional intake, with active support from government and non-governmental agencies. This is consequently widening prospects for parenteral nutritional products. These products are extensively used to assist in nutritional intake of patients with severe illnesses.

High Incidence of Premature Births to Accelerate Parenteral Nutrition Uptake

The scope for parenteral nutrition has been further enhanced in the light of increasing numbers of premature births across multiple regions. It is documented that every year, around 15 million babies are born preterm- before the completion of the 37-week gestation period. Across 184 countries, this rate ranges from 5% to 18%.

Most premature babies suffer from low weight and undeveloped immunity, which puts them at risk. In addition, individuals and healthcare authorities are extensively focusing on limiting mortality due to early birth, thereby driving the use of parenteral lipid emulsions. 

Healthcare infrastructure across the most critical areas are being extensively revamped to accommodate the growing nutritional intake requirements of pre-term infants. This has considerably broadened growth prospects for parenteral nutrition products.

Region-wise Analysis

What are the Growth Prospects for the North American Market?

Increasing Prevalence of Nutritional Deficiency to Augment Adoption

According to Fact.MR, parenteral nutrition revenue is likely to be the largest across North America, expected to gather a market share worth 42% in 2022. Growth is majorly attributed to the increasing prevalence of nutritional inadequacy amongst both adults and children in recent years.

According to Johns Hopkins Medicine, across the United States, a significant proportion of children suffer from malnutrition due to dietary imbalances than due to nutritional deficiencies. About 1% of children across the U.S suffer from chronic malnutrition. Iron deficiency comprises most of the malnutrition cases across the country.

Estimates by the World Health Organization suggest that one in six women (16%) are iron deficient, especially during pregnancy, with the incidence higher among non-Hispanic blacks and Hispanics. Hence, a lot of patients are opting for parenteral nutritional products and services throughout the continent.

How do Growth Prospects Appear across the Asia-Pacific Region?

A Large Population Base and the Consequent Nutritional Requirement Bolstering Prospects

Sales of parenteral nutritional products are expected to grow the fastest across the Asia-Pacific. The presence of a large population base and the consequent rise in cases of inadequate nutritional intake- particularly across the developing world- has heightened growth prospects throughout the region.

Countries such as India represent the bulk of all growth opportunities in the long-run. It is reported that every day, more than 6,000 children below the age of 5 succumb to malnutrition in the country. Most of them are a result of lack of vitamin A, iron iodine, zinc and folic acid. About 57% of preschoolers and their mothers have sub-clinical Vitamin A deficiency.

Likewise, in China, mineral insufficiency comprises the highest form of malnutrition among adults, at around 99.97%, followed by vitamin deficiency (98.8%), overweight & obesity (39.58%) and underweight (~4%). Hence, governments are promoting extensive nutritional intake campaigns, elevating growth prospects. Fact.MR expects the Asia-Pacific market to proliferate at a CAGR of 8% through 2032.

Category-wise Insights

Which Parenteral Nutrient Type is forecast to Remain Dominant?

Single Dose Amino Acid Parenteral Nutrition Solutions to Remain Prominent

By nutrient type, sales of single dose amino acid parenteral nutrition solutions are expected to remain dominant, with an anticipated market share worth 31% in 2022 and beyond. This is attributed to increased usage of amino acid solutions.

Newly procured amino acids possess fewer side effects, thereby enhancing patient benefits. A combination of different amino acid grades have proven to enhance overall biological functioning of the patient. Hence, there is high reliance on this product.

Prospects for Parenteral Lipid Emulsions are expected to Heighten Significantly

Besides single dose amino acids, lipid emulsions are likely to enjoy rapid growth, expanding at a CAGR of 6.7% from 2022 to 2032. Growth is attributed to development of hybrid parenteral lipid emulsions from multiple sources to enhance patient health.

These formulations are manufactured through a combination of fish oil and olive oil. Moreover, the COVID-19 pandemic has prompted healthcare providers to offer parenteral nutrition over enteral approaches, with lipid emulsions proving to be the most convenient option.

Competitive Landscape

Prominent parenteral nutrition products manufacturers are striving to continuously improve their product offerings. They do so by introducing new product lines, consolidating their presence through collaborations and acquiring some small to medium-scale providers among others. Some key developments are as follows:

• In January 2020, Fresenius Kabi completed its clinical trial for SmofKabiven- a new range of lipid emulsions. The product is manufactured from multiple oils, including fish, soybean & olive oils and medium-chain triglycerides.

Key Segments Covered in the Parenteral Nutrition Research Report

• By Nutrient Type :

  • Carbohydrate-based Parenteral Nutrition Products
  • Parenteral Lipid Emulsion
  • Single Dose Amino Acid Parenteral Nutrition Solution
  • Parenteral Nutrition Trace Elements
  • Parenteral Vitamins & Minerals

• By Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA